Please ensure Javascript is enabled for purposes of website accessibility

Cresco Labs Closes Acquisition of Massachusetts Cannabis Grower and Retailer

By Eric Volkman – Updated Feb 7, 2020 at 3:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's about time -- the deal was originally agreed upon in late 2018.

Another slowly developing acquisition in the cannabis industry has been finalized. Cresco Labs (CRLBF -2.32%) announced Friday it has closed its buyout of grower and retailer Hope Heal Health, after being granted approval for the deal by the Massachusetts Cannabis Control Commission.

Although small, the once privately held Hope Heal Health has licenses to grow cannabis and manufacture cannabis products; it also holds a dispensary license for a single retail location, with rights to get two more.

US currency in the shape of a marijuana leaf.

Image source: Getty Images

Happily for Cresco and its shareholders, the Commission's approval comes as the Hope Heal Health dispensary has begun selling recreational-use cannabis in addition to medical marijuana products. The dispensary is located in the eastern Massachusetts town of Fall River, which is on its border with Rhode Island and close to that state's capital and major city of Providence.

As with numerous other buyouts by acquisition-hungry, publicly traded marijuana companies, the Cresco/Hope Heal Health arrangement took time to cross the finish line. The pair originally agreed to the deal at the end of 2018. Then and now, the financial details were not specified.

In a press release announcing the closing, Cresco wrote that with its absorption of Hope Heal Health, it is "stepping into a fully operational, vertically integrated business that is immediately accretive with both positive EBITDA and cash flow." However, again, Cresco declined to provide specifics.

In spite of the obvious progress the finalization of this deal represents, Cresco's stock was down by more than 5% in late afternoon trading Friday.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Cresco Labs Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
CRLBF
$2.57 (-2.32%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.